Proteasome inhibition drastically but reversibly impairs murine lymphocyte development

Cell Death and Differentiation

Volumn 15, Issue 3, 2008, Pages 600-612

  Maseda, D ^a   Meister, S ^a   Neubert, K ^a   Herrmann, M ^a   Voll, R E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 7; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BAGG ALBINO MOUSE; CANCER CELL; CANCER STEM CELL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOTOXICITY; LYMPHOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLYMPHOCYTE; PROTEIN EXPRESSION; PROTEIN INDUCTION; SINGLE DRUG DOSE; T LYMPHOCYTE; THYMOCYTE;

ANIMALS; APOPTOSIS; B-LYMPHOCYTE SUBSETS; BONE MARROW CELLS; BORONIC ACIDS; CELLS, CULTURED; FEMALE; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MICE; MICE, INBRED BALB C; NF-KAPPA B; PRECURSOR CELLS, B-LYMPHOID; PRECURSOR CELLS, T-LYMPHOID; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; PYRAZINES; T-LYMPHOCYTE SUBSETS; THYMUS GLAND;

MURINAE; MUS;

EID: 39449137543     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4402297     Document Type: Article

References (40)

1. Ciechanover A. Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Cell Death Differ 2005; 12: 1178-1190.
2. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO J 1996; 15 3835-3844.
3. Henderson CJ, Aleo E, Foritanini A, Maestro R, Paroni G, Brancolini C. Caspase activation and apoptosis in response to proteasome inhibitors. Cell Death Differ 2005; 12: 1240-1254.
4. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2005; 61: 3071-3076.
5. Callahan MK, Wohlfert EA, Menoret A, Srivastava PK. Heat shock up-regulates Imp2 and Imp7 and enhances presentation of immunoproteasome-dependent epitopes. J Immunol 2006; 177: 8393-8399.
6. Kanaan N, Luo H, Wu J. Proteasome activity is required for T lymphocyte aggregation after mitogen activation. J Cell Biochem 2001; 81 347-356.
7. Claudio E, Brown K, Siebenlist U, NF-kappaB guides the survival and differentiation of developing lymphocytes. Cell Death Differ 2006; 13: 697-701.
8. Mori K. Tripartite management of unfolded proteins in the endoplasmic reticulum. Cell 2000; 101: 451-454.
9. Servida F, Soliqo D, Delia D, Henderson C, Brancolini C, Lombardi L et al. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 2005; 19: 2324-2331.
10. Satou Y, Nosaka K, Koya Y, Yasunaga JI, Toyokuni S, Matsuoka M. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 2004; 18: 1357-1363.
11. Voll RE, Jimi E, Phillips RJ, Barber DF, Rincon M, Hayday AC et al NF-kappa B activation by the pre-T cell receptor serves as a selective survival signal in T lymphocyte development. Immunity 2000; 13: 677-689.
12. von Boehmer H, Fehling HJ. Structure and function of the pre-T cell receptor. Annu Rev Immunol 1997; 15: 433-452.
13. Miosge LA, Goodnow CC. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol Cell Biol 2005; 83: 318-335.
14. Feng B, Cheng S, Pear WS, Liou HC. NF-kB inhibitor blocks B cell development at two checkpoints. Med Immunol 2004; 3: 1.
15. Jimi E, Phillips RJ, Rincon M, Voll R, Karasuyama H, Flavell R et al Activation of NF-kappaB promotes the transition of large CD43+ pre-B cells to small, CD43- pre-B cells. Int Immunol 2005; 17: 815-825.
16. Pasparakis M, Schmidt-Supprian M, Rajewsky K. IkappaB kinase signaling is essential for maintenance of mature B cells. J Exp Med 2002; 196: 743-752.
17. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002; 110: 1389-1398.
18. Rutkowski DT, Arnold SM, Miller CN, Wu J, Li J, Gunnison KM et al. Adaptation to ER stress is mediated by differential stabilities of pro-survival and pro-apoptotic mRNAs and proteins. PLoS Biol 2006; 4: E374.
19. Szegezdi E, Logue SE, Gorman AM, Samall A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO R 2006; 7: 880-885.
20. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007; 67: 1783-1792.
21. Dallaporta B, Pabio M, Maisse C, Daugas E, Loeffler M, Zamzami N et al. Proteasome activation as a critical event of thymocyte apoptosis. Cell Death Differ 2000; 7: 368-373.
22. Lin KI, Baraban JM, Rafan RR. Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration. Cell Death Differ 1998; 5: 577-583.
23. Wang X, Luo H, Chen H, Duguid W, Wu J. Role of proteasomes in T cell activation and proliferation. J Immunol 1998; 160: 788-801.
24. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol 2004; 16: 76-81.
25. Adams J, Palombella VJ, Sauerville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
26. Surh CD, Sprent J. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 1994; 372 100-103.
27. Obeng EA, Carlson LM, Gutman DM, Harrington Jr WJ, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907-4916.
28. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-785.
29. Blanco B, Perez-Simon JA, Sanchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006; 107: 3575-3583.
30. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 002; 109 (Suppl): S81-S96.
31. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E et al Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-1428.
32. Shringanpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT et al Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol 2006; 134: 145-156.
33. Park SH, Bolender N, Eisele F, Kostova Z, Takeuchi J, Coffino P et al The cytoplasmic Hsp70 chaperone machinery subjects misfolded and endoplasmic reticulum import- incompetent protiens to degradation via the ubiquitin-proteasome system. Mol Biol Cell 2007; 18: 153-165.
34. Bush KT, Goldberdg AL, Nigam SK. Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance. J Biol Chem 1997; 272: 9086-9092.
35. Hetz C, Bernassconi P, Fisher J, Lee AH, Bassik MC, Antonsson B et al Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha. Science 2006; 312: 572-576.
36. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB et al. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22: 4953-4963.
37. Wang ZQ, Stingl L, Morrison C, Jantsch M, Los M, Schulze-Osthoff K et al. PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 1997; 11: 2347-2358.
38. Pua HH, Dzhaglov I, Chuck M, Mizushima N, He YW. A critical role for the autophagy gene Atg5 in T cell survival and proliferation. J Exp Med 2007; 204: 25-31.
39. Murata S; Sasaki K, Kishomoto T, Niwa S, Hayashi H, Takahama Y et al Regulation of CD8+ T cell development by thymus-specific proteasornes. Science 2007; 316: 1349-1353.
40. Wils EJ, Comelissen JJ. Thymopoiesis following allogeneic stem cell transplantation: New possibililies for improvement. Blood Rev 2005; 19: 89-98.